Clinical trial NCT06453512: A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema
Official title: A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema Using SCORAD, Patient Questionnaires and Skin Hydration Measurements
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Atopic Eczema
Lead sponsor: Dermal Laboratories Ltd
Sponsor class: INDUSTRY
Collaborators: name: Nottingham University Hospitals NHS Trust
name: Sherwood Forest Hospitals NHS Foundation Trust
First posted: 2024-06-11
Enrollment: 65
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Post market Surveillance
Primary purpose: OTHER

Brief summary: A 4 week, open label, multi-centre (GP setting), post market clinical follow-up study with Doublebase Once in patients of any age and any severity of atopic eczema.

The study will involve patients who are already using emollients as part of their treatment regime, switching to Doublebase Once. Patients will ideally apply the product once daily for 4 weeks and SCORAD assessments will be performed, and patient questionnaires will be completed. A subgroup of adult patients (up to 15 patients) will also undergo skin hydration measurements for the first 8 days to evaluate objective measurements of skin hydration in patients with atopic eczema.

Photographs of the same, representative area of eczema will also be taken for all patients at baseline and after 4 weeks of using Doublebase Once.

Detailed description: This is a prospective, open label, uncontrolled study which will be performed in multiple GP centres, in patients of all ages, who have any severity of atopic eczema. It is anticipated that approximately 75 patients will need to be screened to enrol 65 eligible patients and to complete the study with 50 evaluable patients. This study is being conducted as part of the manufacturer's undertaking to follow up the clinical performance of the device in the post marketing phase (Post Marketing Clinical Follow-up (PMCF)). It will provide additional quantitative information on the product in a real-world environment in various age groups and severities of atopic eczema using validated assessment methods and patient feedback.

Study patients will be asked to use Doublebase Once only once daily for 4 weeks, instead of their usual emollient. If they need to use Doublebase Once more frequently, this will be recorded in their patient diaries, as will any other topical or systemic treatments that they may need to use during the study period (e.g. corticosteroids). Patients will also be able to use Doublebase Once as a soap substitute.

A SCORAD assessment will be performed by the investigator/ research nurse at baseline and then after 1 and 4 weeks of treatment. Patients or their parents/ legal guardians will be asked to complete questionnaires at baseline and after 4 weeks of treatment.

A subgroup of adult patients (of up to 15 patients) will have additional skin hydration measurements (corneometry) taken before switching emollient to Doublebase Once and on 4 more occasions during the first 8 days to evaluate changes in skin hydration in patients with atopic eczema, this will be performed at the same, representative, predetermined selected area of eczema. Measurements will be taken in triplicate (and the mean calculated) and each reading and the mean value will be documented in the patients CRF at baseline, 24 hours after the first application and then again on days 3, 5 and 8 (prior to the application for that day). This subgroup will then continue in the study for the SCORAD and questionnaire follow-up at the same visit timings as the rest of the study population (see 7.12.1.1).

Photographs of one eczema affected area, which will not include any recognisable or identifiable features, private areas or details of the patient, will also be taken at baseline and again after 4 weeks of treatment.

Eligibility criteria: Inclusion Criteria:

* ii) Patients with atopic eczema (personal history or combined personal and familial atopy), of any severity in accordance with the NICE categorisation set out in the table below.

iii) Baseline SCORAD assessment score of at least 15. iv) Patients or their parents/ legal guardians must be able to read and understand the patient information sheet and sign the Consent Form/Assent Form.

v) Patients normally managing their eczema by regular and ongoing use of leave-on emollient(s).

vi) Patients who are not currently using systemic or topically applied antibiotics or Doublebase Once.

vii) Patients who are willing to use Doublebase Once, once daily, as their only leave-on emollient, for 4 weeks.

viii) Patients who are willing to continue to use their standard cleansing regime and/or Doublebase Once as a soap substitute for the duration of the study.

Additional inclusion criterion for subgroup for skin hydration assessments:

i) Baseline corneometry measurement of ≤40 arbitrary units.

Exclusion Criteria:

i) Are currently using or have used in the previous month, any systemic or topically applied antibiotics or Doublebase Once for their atopic eczema.

ii) Have a known history of intolerance or skin sensitivity to any of the ingredients of Doublebase Once (as identified on the patient information sheet and product labelling), or similar products.

iii) Currently participating in any other ongoing research studies or have participated in a study in the previous 30 days.

iv) Patients, or their parents/ legal guardians, who may have difficulties completing the questionnaire, which will be written in English only.

v) Employees of the Sponsor or Investigators, or any immediate family member (partner, offspring, parents, siblings, or sibling's offspring) of such employees.

vi) Patients with any medical condition which, in the opinion of the Investigator, may adversely influence their ability to participate in the study.

Primary outcomes:
measure: Change from baseline in SCORAD after 4 weeks of treatment
timeFrame: 4 weeks
Secondary outcomes:
measure: Change from baseline in SCORAD after 1 week of treatment.
timeFrame: 1 week
measure: SCORAD individual items
timeFrame: 4 weeks
measure: Patient Questionnaire
timeFrame: 4 weeks
measure: Skin Hydration
timeFrame: 8 days
Other outcomes:
measure: Correlation between SCORAD and corneometry
timeFrame: 8 days
Locations:
city: Nottingham
country: United Kingdom
facility: Cripps Medical Centre
state: Nottinghamshire
Study officials:
affiliation: Dermal Laboratories Ltd
name: Simon T Royal, BMedSci BM BS
role: PRINCIPAL_INVESTIGATOR
References: